|
CFAR Diversity, Equity, Inclusion Pipeline Initiative (CDEIPI)
|
Research Initiative
|
OASH
|
NIAID, NIMH, NCI, NHLBI, NIDDK, NINR, NIDCR, NIMHD, NICHD, NIA, FIC, OD/DPCPSI/OAR
|
The overarching goal of the NIH-supported CFAR Diversity, Equity, and Inclusion Pipeline Initiative (CDEIPI) is to support a diverse pool of trainees who are engaged in HIV science at the high school, undergraduate, graduate (masters, doctoral or medical) and post-doctoral levels, including trainees from underrepresented racial and ethnic groups. CDEIPI seeks to develop pathways for these "CFAR Scholars" to successful careers in science and medicine. OASH provided key information and advice in the development of this initiative.
|
|
Characterize Emerging HIV Strains from Blood Donors and Patients
|
Resource Development
|
FDA
|
NIAID
|
This initiative will characterize emerging HIV strains from blood donors and patients to determine viral tropism based on co-receptor usage strains. It will update the global viral panels to analyze multiple, diverse isolates from different parts of the world. This activity is part of the National Institute of Allergy and Infectious Diseases (NIAID) ongoing efforts to develop a well-characterized repository for diagnostics, and drug and vaccine studies.
|
|
Chemical Hazards Emergency Medical Management (CHEMM) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ASPR, CDC
|
NINDS, NLM, NICHD
|
The goal of CHEMM is to provide a comprehensive, user-friendly resource to help enable first responders and other healthcare providers to plan for, respond to, recover from, and mitigate the effects of mass-casualty incidents involving chemicals.
|
|
Chronic Kidney Disease Surveillance System
|
Health Survey
|
CDC
|
NIDDK
|
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) assists the Centers for Disease Control and Prevention (CDC) in its surveillance program of chronic kidney disease, including taking part in an Advisory Group to provide feedback on the program.
|
|
Circulating Estrogens, Androgens, and Progestogens and Risk of Breast Cancer in the PLCO Cohort
|
Research Initiative
|
CDC
|
NCI
|
In a stratified cohort study of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), restricted to postmenopausal women not on menopausal hormone therapy, researchers are using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay recently developed by the Centers for Disease Control and Prevention (CDC) to assess pre-diagnostic circulating levels of the endogenous steroid hormones believed to be involved in breast cancer etiology. Although it is known that endogenous hormones play a critical role in the etiology of breast cancer, the interrelationships among estrogens, androgens, and progesterone in determining risk are not well understood.
|
|
CLARITY - Mammary Gland efforts
|
Research Initiative
|
ATSDR
|
NIEHS
|
Collaboration between Fenton lab at NIEHS and Soto lab at Tufts University to study BPA effects on mammary gland
|
|
Clinical and Translational Research Course for PhD Students
|
Training Initiative
|
FDA
|
CC, NCATS, NCI, NHLBI, NIAID, NIDA, NIDCR, NIDDK, NIGMS, NIMH, NINDS
|
The Clinical and Translational Research Course for PhD Students is a two-week intensive introductory course for graduate students in the basic biomedical sciences who have at least one year of graduate study. The purpose of the course is to demonstrate and highlight the roles of PhD scientists in clinical and translational research, to provide an overview and examples of how basic science and clinical observations lead to translational research, and to increase awareness and access to PhD role models, research resources, and potential career opportunities at the National Institutes of Health (NIH).
|
|
Clinical and Translational Serology Task Force (CTTF)
|
Resource Development
|
CDC, FDA, ASPR
|
NCI, NIAID
|
The National Cancer Institute established a taskforce to catalyze translation of research findings into public health changes. The task force brings together government, academia and industry to provide relevant tools and information related to serology testing to help decisionmakers manage the current and future status of the SARS-CoV-2 pandemic. The task force includes scientists from several disciplines, clinicians, regulatory and public policy experts, and patient advocates.
|
|
Clinical Genome Resource and Genetic Testing Reference Material Program Collaborative Project (ClinGen and GeT-RM Collaborative Project)
|
Resource Development
|
CDC
|
NHGRI
|
ClinGen has partnered with the Centers for Disease Control and Prevention's Genetic Testing Reference Materials Program (or GeT-RM)to develop a publicly available list of expert curated, clinically important genomic variants that provides a foundation for designing comprehensive validation studies and for creating in silico reference materials for clinical genomic test development and validation. In August 2021, ClinGen and GeT-RM published their results in the Journal of Molecular Diagnostics. To assemble the expert curated variant list, members from 36 of ClinGen’s Expert Panels were asked to nominate clinically important variants, including SNPs, CNVs, difficult-to-sequence regions, and complex rearrangements. 546 genomic variants in 84 genes were nominated, including 29 genes on the American College of Medical Genetics and Genomics Secondary Findings v3.0 List. The nominated variants relate to a wide range of diseases, including heritable cancers, inborn errors of metabolism, cardiomyopathy, diabetes, and immune disorders. ClinGen and GeT-RM will continue to solicit feedback from the community and update the list on a regular basis.
|
|
Clinical Immunization Safety Assessment Network (CISA)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID, NHLBI
|
Subcommittee to evaluate myocarditis after COVID vaccination
|